Objective: This analysis was performed to evaluate the efficacy in stroke prevention and
safety of dabigatran in Chinese nonvalvular atrial fibrillation (NVAF) patients enrolled in RE …

Background: The Asian population with atrial fibrillation (AF) have a higher risk of stroke
than the caucasian population and a higher risk of intracranial bleeding when …

Background: Dabigatran is an oral direct thrombin inhibitor recently approved for stroke
prevention in atrial fibrillation (AF) as an alternative to warfarin. The primary advantages of …

Background and Purpose—Whether dabigatran is associated with different risks of
cardiovascular, bleeding events, and mortality from warfarin in Asian patients with …

Background Little is known about the comparative effectiveness and safety of non–vitamin K
antagonist oral anticoagulants (NOAC) compared to warfarin in Chinese atrial fibrillation …

Background Dabigatran, an oral direct thrombin inhibitor, possesses several advantages
over warfarin that can in principle simplify the management of stroke prevention in atrial …

Background: RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an
international multicenter study (18,113 patients from 967 centers in 44 countries) that …

Background In “real-world” practice, anticoagulant therapy is indicated for patients whose
clinical profiles are not addressed in randomized clinical trials. We assessed the …

Background: The study objective was to evaluate long-term safety and effectiveness of
dabigatran 110 mg and 150 mg twice daily (bid) in patients with nonvalvular atrial fibrillation …

Aims We aim to determine the optimal dose of dabigatran in Korean patients with atrial
fibrillation (AF). Methods and results We analysed 1834 patients with non-valvular AF …